Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung
- PDF / 482,254 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 27 Downloads / 200 Views
ORIGINAL PAPER
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non‑small cell lung cancer patients Kenji Morimoto1 · Tadaaki Yamada1 · Ryota Nakamura1 · Yuki Katayama1 · Satomi Tanaka1 · Chieko Takumi2 · Noriya Hiraoka2 · Yuri Ogura3 · Takayuki Takeda3 · Keisuke Onoi4 · Yusuke Chihara4 · Ryusuke Taniguchi5 · Takahiro Yamada5 · Yohei Matsui1 · Osamu Hiranuma6 · Yoshie Morimoto1 · Masahiro Iwasaku1 · Yoshiko Kaneko1 · Junji Uchino1 · Koichi Takayama1 Received: 8 September 2020 / Accepted: 30 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Combined immunotherapy and chemotherapy is a promising standard treatment in patients with advanced non-small cell lung cancer (NSCLC). This study aimed to evaluate the relationship between the combined therapy and pretreatment serum antinuclear antibody (ANA) levels as a prognostic indicator in patients with NSCLC. We retrospectively analyzed patients with advanced NSCLC who were treated with combinatorial immunotherapy and chemotherapy between January and December 2019 at six institutions in Japan. Relationship between ANA status and patients’ characteristics were reviewed. A total of 77 patients with advanced NSCLC were enrolled in the study. Patients were divided into ANA-positive (ANA ≥ 1:160) and ANA-negative (ANA
Data Loading...
